Cover Image
市場調查報告書

靜脈性腳潰瘍(小腿潰瘍) - 開發平台分析

Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 255952
出版日期 內容資訊 英文 71 Pages
訂單完成後即時交付
價格
Back to Top
靜脈性腳潰瘍(小腿潰瘍) - 開發平台分析 Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H2 2016
出版日期: 2016年07月13日 內容資訊: 英文 71 Pages
簡介

由於腿部靜脈高壓,造成皮膚持續受損,就會引發靜脈性腳潰瘍。該部位會受損而形成潰瘍。症狀有按壓時會暫時留下指痕(壓痕水腫),腳踝有充滿體液的腫起,變色的潰瘍四周皮膚變硬、腳感覺變硬,形成倒香檳酒瓶的狀態、白皮膚上小小光滑的部位有小小的紅色斑點(白色萎縮)等。

本報告提供靜脈性腳潰瘍(小腿潰瘍)的治療藥開發平台現況及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊,以及最新的新聞和發表等資料。

簡介

  • 調查範圍

靜脈性腳潰瘍(小腿潰瘍) 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的開發企業

  • Adocia
  • CardioVascular BioTherapeutics, Inc.
  • CoDa Therapeutics, Inc
  • CytoTools AG
  • FirstString Research, Inc.
  • Intralytix, Inc.
  • MacroCure Ltd
  • Pergamum AB
  • RegeneRx Biopharmaceuticals, Inc
  • Smith & Nephew Plc
  • Stratatech Corporation

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • Cathelicidin
  • Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers
  • CL-05
  • CODA-001
  • CureXcell
  • CVBT-141B
  • Granexin
  • HP-802247
  • LL-37
  • Recombinant Protein to Agonize Platelet Derived Growth Factor Receptor for Metabolic and Dermatology Diseases
  • RGN-137
  • WPP-201
  • Venous Leg Ulcers (Crural ulcer)

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8235IDB

Summary

Global Markets Direct's, 'Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H2 2016', provides an overview of the Venous Leg Ulcers (Crural ulcer) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Venous Leg Ulcers (Crural ulcer), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Venous Leg Ulcers (Crural ulcer) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Venous Leg Ulcers (Crural ulcer)
  • The report reviews pipeline therapeutics for Venous Leg Ulcers (Crural ulcer) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Venous Leg Ulcers (Crural ulcer) therapeutics and enlists all their major and minor projects
  • The report assesses Venous Leg Ulcers (Crural ulcer) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Venous Leg Ulcers (Crural ulcer)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Venous Leg Ulcers (Crural ulcer)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Venous Leg Ulcers (Crural ulcer) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Venous Leg Ulcers (Crural ulcer) Overview
  • Therapeutics Development
    • Pipeline Products for Venous Leg Ulcers (Crural ulcer) - Overview
  • Venous Leg Ulcers (Crural ulcer) - Therapeutics under Development by Companies
  • Venous Leg Ulcers (Crural ulcer) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Venous Leg Ulcers (Crural ulcer) - Products under Development by Companies
  • Venous Leg Ulcers (Crural ulcer) - Companies Involved in Therapeutics Development
    • Adocia
    • CardioVascular BioTherapeutics, Inc.
    • CytoTools AG
    • FirstString Research, Inc.
    • MacroCure Ltd.
    • MediWound Ltd.
    • NovaLead Pharma Pvt. Ltd.
    • Pergamum AB
    • RegeneRx Biopharmaceuticals, Inc.
    • Stratatech Corporation
    • Tissue Therapies Limited
  • Venous Leg Ulcers (Crural ulcer) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Biochaperone PDGF-BB - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cell Therapy to Activate Cathelicidin for Diabetic Foot Ulcers and Crural Ulcer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CL-05 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CODA-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CureXcell - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CVBT-141B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EscharEx - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Granexin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LL-37 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NLP-328 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PAC-G - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RGN-137 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stathmin-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VF-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Venous Leg Ulcers (Crural ulcer) - Dormant Projects
  • Venous Leg Ulcers (Crural ulcer) - Discontinued Products
  • Venous Leg Ulcers (Crural ulcer) - Product Development Milestones
    • Featured News & Press Releases
      • May 23, 2016: CytoTools confirms the clinical efficacy of DermaPro in phase II/III trial
      • Dec 17, 2015: Tissue Therapies Provides FDA Regulatory Progress Update
      • Aug 19, 2015: Macrocure Provides Update on Futility Analysis for Phase III Clinical Trial of CureXcell in Venous Leg Ulcers
      • Jul 22, 2015: RegeneRx Receives Notice of Acceptance for Australian Patent for Key TB4 Peptide Fragment
      • Apr 21, 2015: SCRA Technology Ventures Company Shares Phase 2 Results
      • Apr 15, 2015: CytoTools: Recruitment Of Patients Now Complete For European Studies On Diabetic Foot And Ulcus Cruris Indications
      • May 05, 2014: Subsidiary DermaTools Biotech starts European clinical phase II/III trial with wound healing medication DermaPro for ulcus cruris indication
      • Oct 10, 2013: Pergamum announces final data from Phase I/II study of LL-37 in patients with chronic leg ulcers
      • Apr 19, 2013: Pergamum Reaches Last-Patient-Last-Visit In Phase I/II Trial Of LL-37 For Treatment Of Venous Leg Ulcers
      • Jan 09, 2013: CoDa Therapeutics Announces Positive Results From Phase IIb Study Of Nexagon In Chronic Venous Leg Ulcers
      • Sep 11, 2012: Pergamum Announces Dosing Of First Patient In Phase I/II trial Of LL-37 For Hard-to-heal Wounds
      • Mar 26, 2009: RegeneRx Reports Phase II Venous Stasis Trial Results
      • Feb 26, 2009: RegeneRx Updates On Phase II Venous Stasis Trial
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Venous Leg Ulcers (Crural ulcer), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Venous Leg Ulcers (Crural ulcer) - Pipeline by Adocia, H2 2016
  • Venous Leg Ulcers (Crural ulcer) - Pipeline by CardioVascular BioTherapeutics, Inc., H2 2016
  • Venous Leg Ulcers (Crural ulcer) - Pipeline by CytoTools AG, H2 2016
  • Venous Leg Ulcers (Crural ulcer) - Pipeline by FirstString Research, Inc., H2 2016
  • Venous Leg Ulcers (Crural ulcer) - Pipeline by MacroCure Ltd., H2 2016
  • Venous Leg Ulcers (Crural ulcer) - Pipeline by MediWound Ltd., H2 2016
  • Venous Leg Ulcers (Crural ulcer) - Pipeline by NovaLead Pharma Pvt. Ltd., H2 2016
  • Venous Leg Ulcers (Crural ulcer) - Pipeline by Pergamum AB, H2 2016
  • Venous Leg Ulcers (Crural ulcer) - Pipeline by RegeneRx Biopharmaceuticals, Inc., H2 2016
  • Venous Leg Ulcers (Crural ulcer) - Pipeline by Stratatech Corporation, H2 2016
  • Venous Leg Ulcers (Crural ulcer) - Pipeline by Tissue Therapies Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Venous Leg Ulcers (Crural ulcer) - Dormant Projects, H2 2016
  • Venous Leg Ulcers (Crural ulcer) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Venous Leg Ulcers (Crural ulcer), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top